Retrophin (RTRX) PT Raised to $40 at BMO Capital

September 7, 2016 4:14 PM EDT
Get Alerts RTRX Hot Sheet
Price: $19.18 +2.29%

Rating Summary:
    5 Buy, 0 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 11 | Down: 21 | New: 54
Trade RTRX Now!
Join SI Premium – FREE

Find out which companies are about to raise their dividend well before the news hits the Street with's Dividend Insider Elite. Sign-up for a FREE trial here.

BMO Capital analyst Do Kim reiterated an Outperform rating and boosted his price target on Retrophin (NASDAQ: RTRX) to $40.00 (from $28.00) and increase the probability of success for Sparsentan to 45% from 25%, following positive Phase II DUET data.

Kim commented, "While we model an accelerated approval for Sparsentan, we recognize the increased risk regarding an early filing, given little visibility on the likely commercial dose. Our 45% risk adjustment reflects the potential need for a confirmatory Phase III trial prior to regulatory filing."

For an analyst ratings summary and ratings history on Retrophin click here. For more ratings news on Retrophin click here.

Shares of Retrophin closed at $16.32 yesterday.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, Analyst PT Change

Related Entities

BMO Capital

Add Your Comment